Investors' speedy study hopes quashed as Novo Nordisk continues cardiovascular trial

A Sydbank analyst identifies one possible reason why Novo Nordisk dropped 9% on Wednesday, as some might have been surprised that more evidence is needed to back up Wegovy’s cardiovascular benefits.

Photo: Novo Nordisk / PR

Novo Nordisk has decided to keep a large-scale study investigating the cardiovascular benefits of obesity drug Wegovy (semaglutide) running, which could be to the chagrin of investors who hoped for results sooner rather than later.

In the pharmaceutical firm’s Q2 report from Wednesday, Novo Nordisk says that the external independent Data Monitoring Committee, DMC, recommended that the study continue back in July following a review of interim data. Consequently, the study will run as planned until mid-2023.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs